What does this research mean for the field?

The management of noninfectious uveitis is evolving toward precision pharmacology and steroid-sparing immunomodulatory strategies to achieve sustained inflammation control while minimizing corticosteroid-associated toxicity. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Synthesize recent advances in pharmacotherapy for noninfectious uveitis to establish a treat-by-target framework that minimizes corticosteroid-associated ocular toxicity.

August 22, 2026Expert Opinion on Pharmacotherapy

Updated ocular pharmacology for noninfectious uveitis: a comprehensive expert review

View Full Paper

Ask AI

Bookmark

Authors

MSMatthew D Spangler NKNila Kirupaharan JSJohn D. Sheppard

Discussion

Member takes

Overview

Narrative review outlines evolving targeted pharmacotherapies for noninfectious uveitis, highlighting a clinical shift from corticosteroids toward steroid-sparing immunomodulatory strategies.

Key Points

Synthesize recent advances in pharmacotherapy for noninfectious uveitis to establish a treat-by-target framework that minimizes corticosteroid-associated ocular toxicity.
Conducted a narrative review analyzing developments in topical corticosteroids and intravitreal corticosteroid implants, including evidence from the Multicenter Uveitis Steroid Treatment (MUST) trials.
Evaluated clinical literature on steroid-sparing options, such as conventional immunomodulatory therapy, biologic agents, repository corticotropin injection, and emerging small molecules.
The MUST trials demonstrated equivalent visual outcomes between systemic therapy and intraocular steroid implants, while identifying significant ocular complications linked to sustained local corticosteroid exposure.
Therapeutic paradigms are shifting toward precision pharmacology and targeted immunomodulatory agents aligned with specific anatomical and pathophysiological disease features.
Novel sustained-release delivery systems and earlier biologic intervention are expanding the ability to control intraocular inflammation without reliance on long-term steroids.

Cite This Study

Spangler et al. (2026) studied this question.

synapsesocial.com/papers/6a895eeeca7ade938187d2c5 https://doi.org/10.1080/14656566.2026.2715704

View Full Paper

Ask AI

Bookmark

August 22, 2026Expert Opinion on Pharmacotherapy

Updated ocular pharmacology for noninfectious uveitis: a comprehensive expert review

View Full Paper

Ask AI

Bookmark

Authors

MSMatthew D Spangler NKNila Kirupaharan JSJohn D. Sheppard

Discussion

Member takes

Overview

Narrative review outlines evolving targeted pharmacotherapies for noninfectious uveitis, highlighting a clinical shift from corticosteroids toward steroid-sparing immunomodulatory strategies.

Key Points

Synthesize recent advances in pharmacotherapy for noninfectious uveitis to establish a treat-by-target framework that minimizes corticosteroid-associated ocular toxicity.
Conducted a narrative review analyzing developments in topical corticosteroids and intravitreal corticosteroid implants, including evidence from the Multicenter Uveitis Steroid Treatment (MUST) trials.
Evaluated clinical literature on steroid-sparing options, such as conventional immunomodulatory therapy, biologic agents, repository corticotropin injection, and emerging small molecules.
The MUST trials demonstrated equivalent visual outcomes between systemic therapy and intraocular steroid implants, while identifying significant ocular complications linked to sustained local corticosteroid exposure.
Therapeutic paradigms are shifting toward precision pharmacology and targeted immunomodulatory agents aligned with specific anatomical and pathophysiological disease features.
Novel sustained-release delivery systems and earlier biologic intervention are expanding the ability to control intraocular inflammation without reliance on long-term steroids.

Cite This Study

Spangler et al. (2026) studied this question.

synapsesocial.com/papers/6a895eeeca7ade938187d2c5 https://doi.org/10.1080/14656566.2026.2715704

View Full Paper

Ask AI

Bookmark